Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accelerate Diagnostics, IncAXDX · Entity 78156 | Director · 10% owner | December 03, 2024 | December 03, 2024 |
| Aspira Women's Health Inc.AWHL · Entity 7871 | 10% owner | June 05, 2026 | June 09, 2026 |
| BIODESIX INCBDSX · Entity 6053 | 10% owner · Emeritus Director | August 12, 2026 | August 13, 2026 |
| BIOLASE, INCBIOL · Entity 11470 | 10% owner | February 11, 2020 | May 15, 2020 |
| Neos Therapeutics, Inc.NEOS · Entity 141061 | 10% owner | February 17, 2017 | February 17, 2017 |
| QUIDEL CORP /DE/QDEL · Entity 126712 | Director · 10% owner | May 14, 2020 | May 18, 2020 |
| STERICYCLE INCSRCL · Entity 80873 | Director | April 30, 2018 | May 02, 2018 |
| YIELD10 BIOSCIENCE, INC.YTEN · Entity 88195 | 10% owner | December 20, 2023 | May 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accelerate Diagnostics, Inc
Report date December 03, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 8,310,388 |
Reported balance
After 2024-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-12-03 · Sale · Disposed 200,000 · Balance 8,310,388 F1: Represents shares sold by the reporting person to John Patience, a member of the issuer's board of directors, in a private transaction for tax planning purposes. F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust. |
| Common StockSEC Table I · non-derivative | Direct | 20,225 |
Reported balance
Holding disclosure · report date 2024-12-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,225 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,497 |
Reported balance
Holding disclosure · report date 2024-12-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,497 F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the reporting person to John Patience, a member of the issuer's board of directors, in a private transaction for tax planning purposes.
F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.
F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Aspira Women's Health Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 4,046,051 |
Reported balance
After 2026-06-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-05 · Purchase · Acquired 222,222 · Balance 4,046,051 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2029-06-05 | IndirectBy Jack W. Schuler Living Trust | 300,000 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Purchase · Acquired 300,000 · Balance 300,000 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-09-17 | IndirectBy Jack W. Schuler Living Trust | 833,333 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 833,333 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2030-03-12 | IndirectBy Jack W. Schuler Living Trust | 1,801,265 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 1,801,265 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-07-26 | IndirectBy Jack W. Schuler Living Trust | 28,500 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 28,500 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-01-26 | IndirectBy Jack W. Schuler Living Trust | 8,888 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 8,888 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Common StockSEC Table I · non-derivative | Direct | 6,536 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,536 |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2027-07-09 | Direct | 6,536 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 6,536 |
Filing footnotes · ownership attribution and instrument terms
F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.
BIODESIX INC
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 555,810 |
Reported balance
After 2026-08-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-12 · Purchase · Acquired 15,000 · Balance 555,810 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler 2026 GRAT | 1,800,000 |
Reported balance
Holding disclosure · report date 2026-08-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,800,000 F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler 2026 GRAT. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.
F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler 2026 GRAT.
BIOLASE, INC
Report date February 11, 2020 · Filed May 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 739,820 |
Reported balance
After 2020-02-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-02-11 · Sale · Disposed 1,307,931 · Balance 739,820 F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018. F2: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2020-02-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,000 F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018.
F2: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust.
Neos Therapeutics, Inc.
Report date February 17, 2017 · Filed February 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Jack W Schuler Living Trust | 2,338,671 |
Reported balance
Holding disclosure · report date 2017-02-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,338,671 F1: Jack W. Schuler is the sole trustee of the Jack W Schuler Living Trust. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Jack W. Schuler is the sole trustee of the Jack W Schuler Living Trust. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
QUIDEL CORP /DE/
Report date May 14, 2020 · Filed May 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,103,249 |
Reported balance
After 2020-05-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-14 · Exercise / conversion · Acquired 2,100 · Balance 3,103,249 F1: Reflects release of restricted stock units that were previously reported on Form 4. F2: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-14 · Exercise / conversion · Disposed 2,100 · Balance 0 F3: Restricted stock units convert into common stock on a one-for-one basis. F4: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on Form 4.
F2: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any.
F3: Restricted stock units convert into common stock on a one-for-one basis.
F4: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date.
STERICYCLE INC
Report date April 30, 2018 · Filed May 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,078 |
Reported balance
After 2018-04-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-30 · Grant · Acquired 170 · Balance 2,078 F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.
YIELD10 BIOSCIENCE, INC.
Report date December 20, 2023 · Filed May 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 63,789 |
Reported balance
After 2023-12-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-12-20 · Sale · Disposed 36,000 · Balance 63,789 F1: This late filing is due to an inadvertent administrative error. F2: On May 2, 2024 the Issuer effected a 1-for-24 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities beneficially owned following the transaction reported herein has been adjusted and approximated to reflect the Reverse Stock Split. F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This late filing is due to an inadvertent administrative error.
F2: On May 2, 2024 the Issuer effected a 1-for-24 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities beneficially owned following the transaction reported herein has been adjusted and approximated to reflect the Reverse Stock Split.
F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date December 09, 2022 · Filed May 15, 2023
Section 16 reporting ended · disclosed 2023-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 36,595 |
Reported balance
After 2022-12-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-12-09 · Sale · Disposed 10,000 · Balance 36,595 F1: This late filing is due to an inadvertent administrative error. F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This late filing is due to an inadvertent administrative error.
F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2022 Filed May 9, 2023 12:09 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | SaleCommon Stock | 200 | $2.90 | $580.00 |
DisclosureSEC source: 0001175707-23-000121 · form4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 855,915 F1 · date: This late filing is due to an inadvertent administrative error. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust. Read SEC document |
| October 06, 2022 Filed May 9, 2023 12:09 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | SaleCommon Stock | 4,901 | $2.96 | $14,506.96 |
DisclosureSEC source: 0001175707-23-000121 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 856,115 F1 · date: This late filing is due to an inadvertent administrative error. F2 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust. Read SEC document |
| August 26, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 22,681 | $2.41 | $54,674.82 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 18 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 466,666 F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.4495, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 25, 2022 Filed Aug 29, 2022 21:37 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | PurchaseWarrants (Right to buy) · Derivative | 133,333 | Not disclosed Strike: $0.88 | Not disclosed |
DisclosureSEC source: 0001140361-22-031345 · form4.xml · derivative · entry 2 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 133,333 Underlying: Common Stock, par value $0.001 · 133,333 shares Expires 2027-08-25 F3 · security: The terms of the warrants prohibit the holder from exercising the warrants to the extent that the exercise would result in the holder and its affiliates beneficially owning more than 4.99% (or, at the election of the holder and after 61 days' advance notice to the Issuer, 9.99%) of the outstanding shares of common stock. As such, as of the date of the filing of this Form 4, none of the warrants owned by the Reporting Person are currently exercisable. F1 · price: Each share of common stock was purchased together with one warrant to purchase one share of common stock (each share and related warrant, a "unit"), at a price of $0.75 per unit. F3 · derivative.exercise_date: The terms of the warrants prohibit the holder from exercising the warrants to the extent that the exercise would result in the holder and its affiliates beneficially owning more than 4.99% (or, at the election of the holder and after 61 days' advance notice to the Issuer, 9.99%) of the outstanding shares of common stock. As such, as of the date of the filing of this Form 4, none of the warrants owned by the Reporting Person are currently exercisable. F2 · ownership.nature: These shares of common stock and warrants are directly held by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| August 25, 2022 Filed Aug 29, 2022 21:37 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | PurchaseCommon Stock, par value $0.001 | 133,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-031345 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,527,850 F1 · price: Each share of common stock was purchased together with one warrant to purchase one share of common stock (each share and related warrant, a "unit"), at a price of $0.75 per unit. F2 · ownership.nature: These shares of common stock and warrants are directly held by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| August 25, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 8,394 | $2.42 | $20,344.54 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 17 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 489,347 F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.4735, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 24, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 10,888 | $2.50 | $27,230.89 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 16 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 497,741 F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4405 to $2.535, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 23, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 173 | $2.62 | $453.97 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 15 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 508,629 F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.6175 to $2.6228, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 22, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 4,571 | $2.68 | $12,230.62 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 14 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 508,802 F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.598 to $2.736, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 19, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 7,876 | $2.73 | $21,492.82 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 13 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 513,373 F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.7015 to $2.7510, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 18, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 10,833 | $2.80 | $30,372.48 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 12 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 521,249 F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.775 to $2.9895, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 17, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 5,212 | $2.90 | $15,104.90 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 11 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 532,082 F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.8155 to $2.9685, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 16, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 7,718 | $2.88 | $22,244.82 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 10 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 537,294 F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $2.964, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 21:58 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantWarrants (right to buy) · Derivative | 2,471,710 | Not disclosed Strike: $2.12 | Not disclosed |
DisclosureSEC source: 0001104659-22-091932 · tm2223622-1_4seq1.xml · derivative · entry 4 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 2,471,710 Underlying: Common Stock · 2,471,710 shares Expires 2029-08-15 F7 · price: On August 15, 2022, the Issuer entered into an exchange agreement with the Schuler Trust pursuant to which the Schuler Trust exchanged with the Issuer (the "Exchange") $49,905,000 in aggregate principal amount of Notes (face value) held by it for (a) a secured promissory note in an aggregate principal amount of $34,933,500 and (b) a warrant to acquire up to 2,471,710 shares the Issuer's common stock at an exercise price of $2.12 per share. F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust (the "Schuler Trust"). Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 21:58 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Disposition to issuer2.50% Convertible Senior Notes due 2023 · Derivative | Not disclosed | Not disclosed Strike: $30.92 | $49,905,000.00 |
DisclosureSEC source: 0001104659-22-091932 · tm2223622-1_4seq1.xml · derivative · entry 3 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: Not disclosed Underlying: Common Stock · 1,614,065 shares Expires not disclosed F3 · derivative.exercise_price: The initial conversion rate of 32.3428 per $1,000 principal amount of Accelerate Diagnostics, Inc.'s (the "Issuer") 2.50% Convertible Senior Notes due 2023 (the "Notes") is equivalent to an initial conversion price of approximately $30.92 per share of the Issuer's common stock. The initial conversion rate is subject to adjustment upon the occurrence of certain customary events in accordance with the terms of an indenture governing the Notes. F7 · price: On August 15, 2022, the Issuer entered into an exchange agreement with the Schuler Trust pursuant to which the Schuler Trust exchanged with the Issuer (the "Exchange") $49,905,000 in aggregate principal amount of Notes (face value) held by it for (a) a secured promissory note in an aggregate principal amount of $34,933,500 and (b) a warrant to acquire up to 2,471,710 shares the Issuer's common stock at an exercise price of $2.12 per share. F4 · derivative.exercise_date: Holders of the Notes have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances: (i) if the Issuer's stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018; (ii) during the 5 business day period after any 5 consecutive trading day period in which the Notes' trading price is less than 98% of the product of the common stock price times the conversion rate; or (iii) the occurrence of certain corporate events, such as a change of control, merger or liquidation. At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount at the option of the holder regardless of the foregoing circumstances. F5 · derivative.expiration_date: The Notes mature on March 15, 2023, subject to earlier repurchase or conversion in accordance with their terms. F6 · derivative.underlying_shares: Upon conversion of the Notes, the Issuer will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Issuer's election. This number represents the number of shares of common stock that were issuable upon conversion of the $49,905,000 aggregate principal amount of Notes (face value) exchanged by the reporting person pursuant to the Exchange (as defined below) if the Issuer had elected to settle its conversion obligation solely through shares of common stock by delivering a number of shares of common stock at the initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes and cash in lieu of fractional shares of common stock. F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust (the "Schuler Trust"). Read SEC document |
| August 15, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 53,333 | $2.93 | $156,377.69 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 9 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 545,012 F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $3.03, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 12, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 16,667 | $2.65 | $44,237.55 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 8 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 598,345 F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.58 to $2.6955, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 11, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 2,675 | $2.72 | $7,263.70 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 7 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 615,012 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.715 to $2.7165, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 10, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 8,006 | $2.65 | $21,183.88 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 6 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 617,687 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.61 to $2.7285, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 17:52 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Purchase2.50% Convertible Senior Notes due 2023 · Derivative | Not disclosed | Not disclosed Strike: $30.92 | $9,500,000.00 |
DisclosureSEC source: 0001104659-22-088722 · tm2223133-1_4seq1.xml · derivative · entry 3 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: Not disclosed Underlying: Common Stock · 307,256 shares Expires not disclosed F3 · derivative.exercise_price: The initial conversion rate of 32.3428 per $1,000 principal amount of Accelerate Diagnostics, Inc.'s (the "Issuer") 2.50% Convertible Senior Notes due 2023 (the "Notes") is equivalent to an initial conversion price of approximately $30.92 per share of the Issuer's common stock. The initial conversion rate is subject to adjustment upon the occurrence of certain customary events in accordance with the terms of an indenture governing the Notes. F7 · price: The $9,500,000 aggregate principal amount of Notes (face value) were acquired by the reporting person in exchange for the forgiveness of a loan in the amount of approximately $6,352,972 (including interest) owed to the reporting person. F4 · derivative.exercise_date: Holders of the Notes have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances: (i) if the Issuer's stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018; (ii) during the 5 business day period after any 5 consecutive trading day period in which the Notes' trading price is less than 98% of the product of the common stock price times the conversion rate; or (iii) the occurrence of certain corporate events, such as a change of control, merger or liquidation. At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount at the option of the holder regardless of the foregoing circumstances. F5 · derivative.expiration_date: The Notes mature on March 15, 2023, subject to earlier repurchase or conversion in accordance with their terms. F6 · derivative.underlying_shares: Upon conversion of the Notes, the Issuer will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Issuer's election. This number represents the number of shares of common stock issuable upon conversion of the $9,500,000 aggregate principal amount of Notes (face value) purchased by the reporting person if the Issuer elects to settle its conversion obligation solely through shares of common stock by delivering a number of shares of common stock at the initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes and cash in lieu of fractional shares of common stock. F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| August 08, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 6,824 | $2.64 | $18,014.00 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 5 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 625,693 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.574 to $2.685, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 16:14 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Purchase2.50% Convertible Senior Notes due 2023 · Derivative | Not disclosed | $25,898,850.00 Strike: $30.92 | $38,655,000.00 |
DisclosureSEC source: 0001104659-22-087909 · tm2222909-1_4seq1.xml · derivative · entry 3 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: Not disclosed Underlying: Common Stock · 1,250,210 shares Expires not disclosed F3 · derivative.exercise_price: The initial conversion rate of 32.3428 per $1,000 principal amount of Accelerate Diagnostics, Inc.'s (the "Issuer") 2.50% Convertible Senior Notes due 2023 (the "Notes") is equivalent to an initial conversion price of approximately $30.92 per share of the Issuer's common stock. The initial conversion rate is subject to adjustment upon the occurrence of certain customary events in accordance with the terms of an indenture governing the Notes. F7 · price: The purchase price reflects the discount at which the $38,655,000 aggregate principal amount of Notes (face value) were purchased by the reporting person and excludes approximately $375,813 of accrued interest paid by the reporting person in connection with the purchase of the Notes. F4 · derivative.exercise_date: Holders of the Notes have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances: (i) if the Issuer's stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018; (ii) during the 5 business day period after any 5 consecutive trading day period in which the Notes' trading price is less than 98% of the product of the common stock price times the conversion rate; or (iii) the occurrence of certain corporate events, such as a change of control, merger or liquidation. At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount at the option of the holder regardless of the foregoing circumstances. F5 · derivative.expiration_date: The Notes mature on March 15, 2023, subject to earlier repurchase or conversion in accordance with their terms. F6 · derivative.underlying_shares: Upon conversion of the Notes, the Issuer will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Issuer's election. This number represents the number of shares of common stock issuable upon conversion of the $38,655,000 aggregate principal amount of Notes (face value) purchased by the reporting person if the Issuer elects to settle its conversion obligation solely through shares of common stock by delivering a number of shares of common stock at the initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes and cash in lieu of fractional shares of common stock. F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| August 05, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 6,696 | $2.52 | $16,894.01 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 4 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 632,517 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.4765 to $2.535, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 04, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 5,103 | $2.46 | $12,551.34 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 3 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 639,213 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.433 to $2.5305, which sale prices reflect the Stock Split. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 03, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 2,520 | $2.54 | $6,388.96 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 644,316 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.5238 to $2.5463, which sale prices reflect the Stock Split. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (19) to this Form 4. F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| August 02, 2022 Filed Oct 14, 2022 23:11 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 353 | $2.55 | $901.00 |
DisclosureSEC source: 0001209191-22-053711 · doc4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 646,836 F1 · balance_after: The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022 (the "Stock Split"). F2 · ownership.nature: The securities are held by the Jack W. Schuler Living Trust, for which the Reporting Person serves as Trustee. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 21:16 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Purchase2.50% Convertible Senior Notes due 2023 · Derivative | Not disclosed | $1,172,500.00 Strike: $30.92 | $1,750,000.00 |
DisclosureSEC source: 0001104659-22-073645 · tm2219229d1_4.xml · derivative · entry 3 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: Not disclosed Underlying: Common Stock · 56,599 shares Expires not disclosed F3 · derivative.exercise_price: The initial conversion rate of 32.3428 per $1,000 principal amount of Accelerate Diagnostics, Inc.'s (the "Issuer") 2.50% Convertible Senior Notes due 2023 (the "Notes") is equivalent to an initial conversion price of approximately $30.92 per share of the Issuer's common stock. The initial conversion rate is subject to adjustment upon the occurrence of certain customary events in accordance with the terms of an indenture governing the Notes. F7 · price: The purchase price reflects the discount at which the $1,750,000 aggregate principal amount of Notes (face value) were purchased by the reporting person. F4 · derivative.exercise_date: Holders of the Notes have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances: (i) if the Issuer's stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018; (ii) during the 5 business day period after any 5 consecutive trading day period in which the Notes' trading price is less than 98% of the product of the common stock price times the conversion rate; or (iii) the occurrence of certain corporate events, such as a change of control, merger or liquidation. At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount at the option of the holder regardless of the foregoing circumstances. F5 · derivative.expiration_date: The Notes mature on March 15, 2023, subject to earlier repurchase or conversion in accordance with their terms. F6 · derivative.underlying_shares: Upon conversion of the Notes, the Issuer will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Issuer's election. This number represents the number of shares of common stock issuable upon conversion of the $1,750,000 aggregate principal amount of Notes (face value) purchased by the reporting person if the Issuer elects to settle its conversion obligation solely through shares of common stock by delivering a number of shares of common stock at the initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes and cash in lieu of fractional shares of common stock. F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 16:22 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantEmployee Restricted Stock Units · Derivative | 75,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-016062 · wf-form4_165420130028425.xml · derivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,949 Underlying: Common Stock · 75,949 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on May 31, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:15 UTC | BIODESIX INC BDSX · Entity 6053 | GrantRestricted Stock Units · Derivative | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020786 · form4.xml · derivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock and has no expiration date. F3 · shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.exercise_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F2 · derivative.expiration_date: These RSUs will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · derivative.underlying_shares: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. F3 · balance_after: The Compensation Committee of the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 1, 2023, of an additional 62,500 RSUs that will vest in full on March 31, 2023, generally subject to the reporting person's continued service with the Issuer. In the event the reporting person's continued service on the Board terminates other than for cause, the option will vest on a prorated basis based on the number of full months of service the reporting person completed during the applicable vesting period. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:35 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 2,793,296 | $1.79 | $4,999,999.84 |
DisclosureSEC source: 0001567619-22-008352 · doc1.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 11,256,460 F1 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F1 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:59 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseWarrant (right to buy) · Derivative | 4,000,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0000899243-22-013373 · doc4.xml · derivative · entry 8 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,000,000 Underlying: Common Stock · 4,000,000 shares Expires 2027-03-31 F2 · price: Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25. F1 · ownership.nature: The securities are held by the Schuler Education Foundation (formerly the Schuler Family Foundation), for which the Reporting Person serves as President. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:59 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 4,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-013373 · doc4.xml · nonDerivative · entry 6 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,911,804 F2 · price: Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25. F1 · ownership.nature: The securities are held by the Schuler Education Foundation (formerly the Schuler Family Foundation), for which the Reporting Person serves as President. Read SEC document |
| February 10, 2022 Filed Apr 4, 2022 20:59 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | SaleCommon Stock | 800 | $0.35 | $283.84 |
DisclosureSEC source: 0000899243-22-013373 · doc4.xml · nonDerivative · entry 5 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,911,804 F1 · ownership.nature: The securities are held by the Schuler Education Foundation (formerly the Schuler Family Foundation), for which the Reporting Person serves as President. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 16:23 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 41,912 | $3.94 | $165,133.28 |
DisclosureSEC source: 0001628280-22-001108 · wf-form4_164271381090600.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,737,047 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.86 to $3.95, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 16:22 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 31,219 | $3.89 | $121,441.91 |
DisclosureSEC source: 0001628280-22-001029 · wf-form4_164254094040277.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,695,135 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.80 to $4.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 16:22 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 100,000 | $4.03 | $403,000.00 |
DisclosureSEC source: 0001628280-22-001029 · wf-form4_164254094040277.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,663,916 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.96 to $4.19, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 16:32 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 45,226 | $4.34 | $196,280.84 |
DisclosureSEC source: 0001628280-22-000811 · wf-form4_164202315922865.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,563,916 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.32 to $4.40, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 16:09 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 10,000 | $4.93 | $49,300.00 |
DisclosureSEC source: 0001628280-22-000423 · wf-form4_164150332087724.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,518,690 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.92 to $4.94, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 16:16 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 997 | $4.95 | $4,935.15 |
DisclosureSEC source: 0001628280-22-000181 · wf-form4_164133096651797.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,508,690 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.91 to $4.96, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 22:04 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 2,298,850 | $4.35 | $9,999,997.50 |
DisclosureSEC source: 0001567619-22-000278 · doc1.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 8,463,164 F1 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F1 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| December 30, 2021 Filed Jan 31, 2022 11:02 UTC Amendment | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 2,298,850 | $4.35 | $9,999,997.50 |
DisclosureSEC source: 0000905148-22-000138 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 8,463,164 F1 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F1 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 16:17 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 27,062 | $4.83 | $130,709.46 |
DisclosureSEC source: 0001628280-21-025683 · wf-form4_164089905779240.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,507,693 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.90, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 16:17 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 30,000 | $4.87 | $146,100.00 |
DisclosureSEC source: 0001628280-21-025683 · wf-form4_164089905779240.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,480,631 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.79 to $4.96, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 15:41 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 54,541 | $4.73 | $257,978.93 |
DisclosureSEC source: 0001628280-21-025522 · wf-form4_164020568143037.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,450,631 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.68 to $4.80, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| December 17, 2021 Filed Dec 21, 2021 15:37 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 74,127 | $4.98 | $369,152.46 |
DisclosureSEC source: 0001628280-21-025473 · wf-form4_164011905009893.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,396,090 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.82 to $5.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 15:39 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 20,000 | $4.60 | $92,000.00 |
DisclosureSEC source: 0001628280-21-025386 · wf-form4_164003277151994.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,321,963 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.53 to $4.65, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 15:34 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 17,050 | $4.38 | $74,679.00 |
DisclosureSEC source: 0001628280-21-025310 · wf-form4_163977324505446.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,301,963 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.40, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 13:48 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 1,000,000 | $5.00 | $5,000,000.00 |
DisclosureSEC source: 0001628280-21-024199 · wf-form4_163829806872032.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 18,284,913 F1 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 15:29 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 48,987 | $5.06 | $247,874.22 |
DisclosureSEC source: 0001628280-21-024104 · wf-form4_163778573941002.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 17,284,913 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.02 to $5.15, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 19:51 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 20,000 | $6.34 | $126,756.00 |
DisclosureSEC source: 0001567619-21-021147 · doc1.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 6,164,314 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.00 to $6.40, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F1 · ownership.direct: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. F1 · ownership.nature: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.